Explore

Ozempic Approved for Kidney Disease Risk Reduction in Type 2 Diabetes Patients

Ozempic Approved for Kidney Disease Risk Reduction in Type 2 Diabetes Patients

Ozempic, known generically as semaglutide, received a new indication in January 2025 for reducing the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease. This approval follows the FLOW trial conducted in 2024. Originally approved in December 2017 for managing blood sugar in adults with type 2 diabetes, Ozempic's label was expanded in January 2020 to include lowering the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes and known heart disease. The U.S. Food and Drug Administration (FDA) also declared the semaglutide shortage resolved in February 2025, which means compounded versions, not FDA-approved or tested for sterility and potency, are no longer permitted for routine mass production. This resolution and the new indication are leading to a larger user base, prompting increased online discussions about injection site reactions.

FDA Issues Final Guidance on Prescription Drug Use-Related Software, Clarifying Regulatory Approach for Mobile Apps

FDA Issues Final Guidance on Prescription Drug Use-Related Software, Clarifying Regulatory Approach for Mobile Apps

The U.S. Food and Drug Administration (FDA) released final guidance on October 20, 2026, titled "Regulatory Considerations for Prescription Drug Use-Related Software." This guidance outlines how the FDA intends to apply its drug labeling authorities to software, such as mobile applications, that drug sponsors distribute for use with their prescription drugs. Concurrently, the Obesity Action Coalition (OAC) published new research detailing patient preferences for prescription companion apps, emphasizing the importance of clear medication instructions, data privacy explanations, and patient control over shared health information. The OAC's findings indicate that 86% of surveyed patients would be influenced by FDA review when deciding to use an app, highlighting the significance of regulatory oversight in patient trust and adoption of digital health tools. The FDA's guidance clarifies when such software should be included in official drug information and when drug companies must submit app content to the agen...

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Issues Final Guidance on Prescription Drug Use-Related Software Labeling

FDA Issues Final Guidance on Prescription Drug Use-Related Software Labeling

On October 20, 2026, the U.S. Food and Drug Administration (FDA) released its final guidance titled 'Regulatory Considerations for Prescription Drug Use-Related Software.' This guidance, which finalizes a draft from September 2023, outlines how the FDA will apply its drug labeling authorities to software, such as mobile applications, that drug sponsors distribute for use with their prescription drugs. It also covers Center for Drug Evaluation and Research (CDER)-led or Center for Biologics Evaluation and Research (CBER)-led combination products. The guidance clarifies when software output is considered FDA-required or promotional labeling, when software should be described in a drug’s prescribing information (PI), and what information sponsors must submit to the FDA. This includes software disseminated by or on behalf of a drug sponsor that produces 'end-user output' related to the drug products. The FDA considers this end-user output, which is any content presented to a patient, caregiver, or healthcare p...

HHS Secretary Robert F. Kennedy Jr. Eases Restrictions on Six Peptides Against FDA Advice

HHS Secretary Robert F. Kennedy Jr. Eases Restrictions on Six Peptides Against FDA Advice

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has announced an interim enforcement discretion policy allowing broader use of six previously restricted peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. This decision was made against the advice of the Food & Drug Administration (FDA). The policy permits compounding pharmacies to prepare these peptides without HHS enforcement action, provided they adhere to specific regulations. These regulations include sourcing raw ingredients from FDA-registered manufacturers following good manufacturing practices, possessing a certificate of analysis for purity and lack of contaminants, ensuring each product contains only one peptide, and limiting peptides to specific forms (e.g., intranasal for Semax). The peptides will still require a prescription from a licensed physician and cannot be purchased over the counter. Secretary Kennedy has been a vocal advocate for peptide use, stating that this policy aims to discourage the use of research-use-...

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

Within the past year, the FDA has approved two gene therapies for inherited immune disorders: etuvetidigene autotemcel (etu-cel, Waskyra) for Wiskott-Aldrich syndrome (WAS) and Exagamglogene autotemcel (Casgevy) for sickle cell disease and transfusion-dependent β-thalassemia. Etu-cel, approved in December 2025, is for WAS patients aged 6 months and older who are eligible for hematopoietic stem cell transplantation but lack a suitable donor. Casgevy's eligibility was expanded in July 2026 to include patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia, lowering the previous age threshold. While these approvals offer new treatment options, experts at the 2026 American Society for Transplantation and Cellular Therapy Gene Therapy Summit emphasized ongoing challenges in manufacturing quality, long-term safety, and patient access. For instance, Casgevy's label requires lifelong malignancy surveillance and regular blood counts, highli...

Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead Sciences, Inc. and its company Kite have announced that they will present 23 new data presentations, including seven oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled from December 12–15, 2026. These presentations will highlight significant advancements across Gilead and Kite’s pipeline and portfolio, focusing on treatments for blood cancers and autoimmune disorders. Key data includes 18-month minimum follow-up results for anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (RRMM) from the pivotal Phase 2 iMMagine-1 study. This data forms the basis of a Biologics License Application (BLA) currently under review by the U.S. Food and Drug Administration (FDA), with a target decision date of December 23, 2026. Additionally, five-year follow-up data for Yescarta® (axicabtagene ciloleucel) in first-line high-risk large B-cell lymphoma (LBCL) will be presented, along with early clinical results for KITE-753 in B-cell ...

Baird Medical and Alpmed Submit IRE System for FDA 510(k) and EU CE Approval

Baird Medical and Alpmed Submit IRE System for FDA 510(k) and EU CE Approval

Baird Medical Investment Holdings Limited, a medical device company specializing in minimally invasive ablation technologies, announced that its strategic partner, Tianjin Yuanshan Medical Technology Co., Ltd. (Alpmed), has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA). Concurrently, an application for CE conformity assessment has been submitted in the European Union for an irreversible electroporation (IRE) system. This system is designed for soft tissue ablation and holds potential for treating various tumor types. The submissions were completed less than three months after the cooperation agreement between Baird Medical and Alpmed was signed. Baird Medical is managing global regulatory interactions and holds worldwide commercial rights for the IRE system. The companies are aiming for potential U.S. FDA 510(k) clearance and EU CE marking in 2027, contingent on the regulatory review processes.

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

The recent U.S. midterm elections highlighted a negative public sentiment towards artificial intelligence, with voters rejecting data centers—essential for powering AI—on numerous ballot measures across several states. These results align with polling data indicating that many Americans believe AI causes more harm than good. This widespread public attitude raises questions about how it will influence future legislation and policy regarding AI use in health care. Key issues for lawmakers next year include state bills proposing 'sandboxes' for testing AI products and national legislation aimed at clarifying the Food and Drug Administration's (FDA) authority over AI, as well as reimbursement policies for AI-driven health technologies.

Senator Duckworth Seeks FDA Clarification on Estradiol Transdermal Patch Shortage

Senator Duckworth Seeks FDA Clarification on Estradiol Transdermal Patch Shortage

U.S. Senator Tammy Duckworth (D-IL) has formally requested that federal regulators clarify their plans to mitigate an ongoing shortage of estradiol transdermal patches. According to Senator Duckworth, this shortage is making it more difficult for women to effectively manage the symptoms associated with menopause. Her inquiry to the Food and Drug Administration (FDA) seeks detailed information on the root causes of the supply disruption and the specific actions the agency intends to take to resolve the issue and ensure consistent availability of this critical medication.

Whole Foods Market Recalls Ashwagandha Supplement Due to Salmonella Risk

Whole Foods Market Recalls Ashwagandha Supplement Due to Salmonella Risk

Vitality Works Inc. has initiated a recall of 120-count bottles of 365 Whole Foods Market Ashwagandha in its Standardized and Full Spectrum Blend formulation. The recall, announced by the Food and Drug Administration (FDA) on October 30, is due to concerns about possible salmonella contamination. The affected product, lot number 2025-26227, has an expiration date of October 13, 2028. Sales of these capsules occurred between November 24, 2025, and October 20, 2026. The supplement was sold nationwide through Amazon and in Whole Foods Market stores across 30 states and Washington, D.C. Routine testing of a retail-purchased unit revealed the potential contamination, though Vitality Works has not reported any illnesses related to the recall.